This study found that 5-alpha reductase inhibitors had the highest association with erectile dysfunction reports among medications analyzed in the FDA's national pharmacovigilance database.
2 citations
,
July 2022 in “Sexual Medicine” This study found that 5-α reductase inhibitors and neuropsychiatric medications were most frequently reported for erectile dysfunction in a national pharmacovigilance database from 2010 to 2020.
2152 citations
,
November 2013 in “Urologia Internationalis” This study reviews the significant prevalence of organic etiologies, especially vascular causes, in erectile dysfunction among men under 40 and emphasizes thorough evaluation and consideration of treatment options like exercise and PDE-5 inhibitors.
11 citations
,
March 2019 in “Journal of The American Academy of Dermatology” This review identifies evidence of sexual adverse effects, particularly linked to finasteride, in men using systemic dermatologic medications but reports no new clinical findings.
1 citations
,
July 2023 in “F&S Reviews” This review highlights that various commonly prescribed medications for chronic conditions may impact male fertility by affecting hormone secretion, sperm production, ejaculation, erectile function, and libido, although conclusive evidence is limited to specific drug groups.